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Dear Editor,
Acquired deficiency of factor X (FX) is commonly found
during antivitamin K therapy in prevention of thrombosis or
as a consequence of liver disease [1]. Less frequently, it has
been observed as an isolated deficiency in a number of disease
states. It has been associated with amyloidosis and hemato-
logic malignancies [2], and few non amyloid-related cases
have been reported. Association with solid tumors is rare
[3–5]. We would like to present a patient with a transitional
cell carcinoma who developed a FX deficiency.
A 67-year-old man was diagnosed with a localized transi-
tional cell carcinoma of the bladder. Hewas first admitted to our
hospital in January 2014 for a second-opinion consultation.
Transurethral resection of the bladder took place and neoadju-
vant chemotherapy was administered at our hospital, followed
by a cystectomy. During follow-up, suspicious lesions were
noticed on medical imaging and a lung biopsy was carried
out. Pathological examination revealed a metastasis of the tran-
sitional cell carcinoma. The patient subsequently received ste-
reotactic body radiotherapy to all lung lesions yet had progres-
sive disease 6 months later. He was then enrolled in a clinical
trial (NCT02826564) in which he received pembrolizumab
(Keytruda) and stereotactic body radiation therapy to one lung
lesion according to the study protocol [6].
During follow-up, prothrombin time (PT), activated partial
thromboplastin time (aPTT), and fibrinogen concentration were
measured to assess his blood’s clotting status. First measure-
ments were within reference ranges, but after the lung metasta-
ses were noticed and prior to administration of pembrolizumab,
a prolongation of the PT (20s; reference ranges 11.5–14.5 s) and
aPTT (51 s; reference ranges 28.9–38.1 s) was detected (Fig. 1).
In the laboratory diagnostic workup, mixing patient’s plas-
ma with normal pooled plasma showed correction of aPTT
(37.6 s) and PT (14.2 s). Clotting factor activities for the ex-
trinsic factors were determined by a one-stage clotting assay in
a 1:10 sample predilution. Factor II, V, and VII levels were
within normal ranges with 105, 71, and 98% activity but FX
activity was 21% (factor reference ranges 70–120%). Testing
was repeated in higher predilutions of 1:40 and 1:100, without
increase of FX activity (20%). These findings were confirmed
3 weeks later.
In FX deficiencies, FX activity correlates relatively well
with bleeding and may be provoked by levels lower than
10% [1, 7]. If no active bleeding is diagnosed, as in our patient,
careful monitoring and treatment of the underlying disease are
sufficient. If bleeding occurs, it can be treated with prothrom-
bin complex concentrate or plasma, keeping the target FX
level above 20% of the normal reference population [7].
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This is, to our knowledge, the first case of an acquired defi-
ciency of FX associated with an urothelial carcinoma. We sug-
gest that there might be a link with metastasis of solid tumors
[4, 5], as the FX deficiency occurred simultaneously with the
presence of metastases, in accordance with the previously pub-
lished articles discussing this deficiency in solid tumors with
metastasis. This theory is consistent with the status quo of the
lab results and progressive lesions on medical imaging.
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Fig. 1 aPTT and PT results
546 Ann Hematol (2018) 97:545–546
